The Quest to Repair What Multiple Sclerosis Takes Away
Summary
Quantum BioPharma is advancing Lucid-MS, a first-in-class drug candidate designed to protect myelin and address the underlying damage in multiple sclerosis. The company has completed key toxicity studies, filed its IND with the FDA, and prepared for phase 2 testing in MS patients. It also entered a clinical collaboration with Allucent and launched a joint imaging study with Massachusetts General Hospital to validate a PET tracer that can measure myelin integrity. The article frames Lucid-MS as a potential new approach for a large and underserved MS market, while also noting comparable progress from other biotech companies in autoimmune and inflammatory disease. The piece is primarily a development update on a pharmaceutical program, not a financing or corporate transaction story.